ResMed Launches $450M Accelerated Buyback Funded by MatrixCare Sale
RMD sits 29% above its 52-week low of $180.265.
Summary
ResMed entered a $450 million accelerated share repurchase agreement with Citibank, funded by proceeds from the MatrixCare divestiture and cash on hand. The ASR is set to settle by December 2026. This follows the $490 million MatrixCare sale announced in July and the company's first-ever revenue guidance in August. The buyback signals management's confidence in cash generation and returns capital to shareholders, though the amount is modest relative to ResMed's $33 billion market cap. Watch for the final settlement and any additional repurchase activity in the December quarter.
At the time of this announcement, RMD was trading at $231.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $33.4B. The 52-week trading range was $180.27 to $284.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.